Literature DB >> 8619009

GM1 ganglioside administration partially counteracts the morphological changes associated with haloperidol treatment within the dorsal striatum of the rat.

C K Meshul1, R K Stallbaumer, C Allen.   

Abstract

Haloperidol, a typical antipsychotic drug, causes an increase in the mean percentage of synapses within the situation containing a discontinuous, or perforated, postsynaptic density (PSD) following 1 month of treatment (Meshul et al. 1994). This effect is not observed with the atypical antipsychotic drug, clozapine, following subchronic administration (Meshul et al. 1992a). This morphological change is also associated with an increase in the density of dopamine D2 receptors. The synapses containing the perforated PSD are asymmetrical and the nerve terminals contain the neurotransmitter, glutamate, as demonstrated by immunocytochemistry. We have also shown that subchronic treatment with haloperidol (0.5 mg/kg per day, 30 days) results in a decrease in the density of glutamate immunoreactivity within asymmetric nerve terminals associated with perforated and non-perforated PSDs (Meshul and Tan 1994). This could be due to an increase in glutamate release, perhaps due to activation of corticostriatal synapses. Agnati et el. (1983a) reported that administration of GM1 ganglioside blocks the increase in dopamine D2 receptors following haloperidol treatment. GM1 has also been shown to attenuate the release of glutamate (Nicoletti et al. 1989). In order to determine if similar treatment with ganglioside could block the haloperidol-induced ultrastructural changes notes above, rats were co-administered GM1 (10 mg/kg per day) and haloperidol (0.5 mg/kg per day) for 30 days. We report that GM1 blocked the haloperidol-induced increase in striatal asymmetric synapses containing a perforated PSD, but had no effect on the increase in dopamine D2 receptors or the decrease in nerve terminal glutamate immunoreactivity. GM1, either alone or co-administered with haloperidol, also caused a small, but significant, increase in the density of all asymmetric synapses within the striatum. It is possible that the effect of GM1 in attenuating the haloperidol-induced change in glutamate synapses with perforated PSDs is primarily postsynaptic, since GM1 did not block the change in density of glutamate immunoreactivity within asymmetric nerve terminals.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8619009     DOI: 10.1007/bf02246494

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  46 in total

1.  Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment.

Authors:  J S Schneider; A Pope; K Simpson; J Taggart; M G Smith; L DiStefano
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

2.  Induction of long-term potentiation is associated with an increase in the number of axospinous synapses with segmented postsynaptic densities.

Authors:  Y Geinisman; L deToledo-Morrell; F Morrell
Journal:  Brain Res       Date:  1991-12-06       Impact factor: 3.252

Review 3.  The functional anatomy of basal ganglia disorders.

Authors:  R L Albin; A B Young; J B Penney
Journal:  Trends Neurosci       Date:  1989-10       Impact factor: 13.837

Review 4.  Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA).

Authors:  O Hornykiewicz
Journal:  Br Med Bull       Date:  1973-05       Impact factor: 4.291

5.  The small pyramidal neuron of the rat cerebral cortex. The synapses upon dendritic spines.

Authors:  A Peters; I R Kaiserman-Abramof
Journal:  Z Zellforsch Mikrosk Anat       Date:  1969-09-22

Review 6.  The effect of chronic neuroleptic administration on cerebral dopamine receptor function.

Authors:  M N Rupniak; P Jenner; C D Marsden
Journal:  Life Sci       Date:  1983-05-16       Impact factor: 5.037

7.  Sodium-dependent isomerization of dopamine D-2 receptors characterized using [125I]epidepride, a high-affinity substituted benzamide ligand.

Authors:  K A Neve; R A Henningsen; J M Kinzie; T De Paulis; D E Schmidt; R M Kessler; A Janowsky
Journal:  J Pharmacol Exp Ther       Date:  1990-03       Impact factor: 4.030

8.  GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats.

Authors:  O A Andreassen; H A Jørgensen
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

9.  Fine structure of meganeurites and secondary growth processes in feline GM1-gangliosidosis.

Authors:  D P Purpura; G D Pappas; H J Baker
Journal:  Brain Res       Date:  1978-03-17       Impact factor: 3.252

10.  Glutamine and aspartate loading of synaptosomes: a reevaluation of effects on calcium-dependent excitatory amino acid release.

Authors:  H T McMahon; D G Nicholls
Journal:  J Neurochem       Date:  1990-02       Impact factor: 5.372

View more
  1 in total

1.  Correlation of vacuous chewing movements with morphological changes in rats following 1-year treatment with haloperidol.

Authors:  C K Meshul; O A Andreassen; C Allen; H A Jørgensen
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.